Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Atazanavir | Calcium silicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Calcium silicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Calcium silicate. |
| Dabigatran etexilate | Calcium silicate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Calcium silicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Calcium silicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Calcium silicate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Calcium silicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Calcium silicate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Calcium silicate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Calcium silicate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | Calcium silicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Pazopanib | Calcium silicate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Calcium silicate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dolutegravir | Calcium silicate can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Calcium silicate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The risk or severity of adverse effects can be increased when Tolevamer is combined with Calcium silicate. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Calcium silicate. |
| Captopril | Calcium silicate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Calcium silicate. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Calcium silicate. |
| Chloroquine | Calcium silicate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Elvitegravir | Calcium silicate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hyoscyamine | Calcium silicate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Calcium silicate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mecamylamine | Calcium silicate may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Memantine | Calcium silicate may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Penicillamine | Calcium silicate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quinidine | Calcium silicate may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Calcium silicate. |
| Allopurinol | The therapeutic efficacy of Allopurinol can be decreased when used in combination with Calcium silicate. |
| Raltegravir | The serum concentration of Raltegravir can be decreased when it is combined with Calcium silicate. |
| Mesalazine | Calcium silicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolate mofetil | Calcium silicate can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | Calcium silicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Calcium silicate. |
| Ketoconazole | Calcium silicate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiethylperazine | Calcium silicate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promazine | Calcium silicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prochlorperazine | Calcium silicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlorpromazine | Calcium silicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Triflupromazine | Calcium silicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluphenazine | Calcium silicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thioridazine | Calcium silicate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Moricizine | Calcium silicate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trifluoperazine | Calcium silicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perphenazine | Calcium silicate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mesoridazine | Calcium silicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetophenazine | Calcium silicate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promethazine | Calcium silicate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Alimemazine | Calcium silicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrimeprazine | Calcium silicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Periciazine | Calcium silicate can cause a decrease in the absorption of Periciazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acepromazine | Calcium silicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aceprometazine | Calcium silicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipotiazine | Calcium silicate can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thioproperazine | Calcium silicate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| BL-1020 | Calcium silicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cyamemazine | Calcium silicate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylene blue | Calcium silicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Propiopromazine | Calcium silicate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perazine | Calcium silicate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Butaperazine | Calcium silicate can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlorproethazine | Calcium silicate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiazinam | Calcium silicate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dixyrazine | Calcium silicate can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perphenazine enanthate | Calcium silicate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Calcium silicate. |
| Doxycycline | Calcium silicate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lymecycline | Calcium silicate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clomocycline | Calcium silicate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxytetracycline | Calcium silicate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Demeclocycline | Calcium silicate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetracycline | Calcium silicate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metacycline | Calcium silicate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Minocycline | Calcium silicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarecycline | Calcium silicate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Omadacycline | Calcium silicate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Penimepicycline | Calcium silicate can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Triethylenetetramine | Calcium silicate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosuvastatin | Calcium silicate can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pamidronic acid | The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium silicate. |
| Zoledronic acid | The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium silicate. |
| Alendronic acid | The serum concentration of Alendronic acid can be decreased when it is combined with Calcium silicate. |
| Ibandronate | The serum concentration of Ibandronate can be decreased when it is combined with Calcium silicate. |
| Clodronic acid | The serum concentration of Clodronic acid can be decreased when it is combined with Calcium silicate. |
| Risedronic acid | The serum concentration of Risedronic acid can be decreased when it is combined with Calcium silicate. |
| Etidronic acid | The serum concentration of Etidronic acid can be decreased when it is combined with Calcium silicate. |
| Tiludronic acid | The serum concentration of Tiludronic acid can be decreased when it is combined with Calcium silicate. |
| Incadronic acid | The serum concentration of Incadronic acid can be decreased when it is combined with Calcium silicate. |
| Betamethasone | The bioavailability of Betamethasone can be decreased when combined with Calcium silicate. |
| Fluticasone propionate | The bioavailability of Fluticasone propionate can be decreased when combined with Calcium silicate. |
| Triamcinolone | The bioavailability of Triamcinolone can be decreased when combined with Calcium silicate. |
| Prednisone | The bioavailability of Prednisone can be decreased when combined with Calcium silicate. |
| Fludrocortisone | The bioavailability of Fludrocortisone can be decreased when combined with Calcium silicate. |
| Hydrocortisone | The bioavailability of Hydrocortisone can be decreased when combined with Calcium silicate. |
| Prednisolone | The bioavailability of Prednisolone can be decreased when combined with Calcium silicate. |
| Methylprednisolone | The bioavailability of Methylprednisolone can be decreased when combined with Calcium silicate. |
| Trilostane | The bioavailability of Trilostane can be decreased when combined with Calcium silicate. |
| Budesonide | The bioavailability of Budesonide can be decreased when combined with Calcium silicate. |